Why the study?
Do beta-blockers reduce cardiovascular morbidity and mortality in patients with diabetes mellitus?
Do beta-blockers reduce cardiovascular morbidity and mortality in patients with diabetes mellitus?
This review highlights that beta-blockers, particularly lipophilic agents, are cardioprotective in diabetic patients and that fears of adverse effects limiting their use are largely unfounded.
Supports lipophilic beta-blockers in diabetes despite historical concerns; leaves open need for dedicated RCTs to confirm benefit.
This paper reviews the role of beta-blockers in the prevention of cardiovascular morbidity and mortality in patients with diabetes mellitus. There is good evidence from randomized controlled trials that beta-blockers, in particular the lipophilic agents, substantially reduce cardiovascular mortality and morbidity. However, hitherto beta-blockers have been underused in diabetic patients, perhaps because of perceived risks of beta-blocker therapy. Reappraisal of the evidence suggests that the traditional reluctance to use beta-blockers in this group is based on fears of adverse effects that are largely unfounded.
No takes yet. Share an insight, caveat, or question.
Landray et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: